Retinopathy of prematurity (ROP) remains a significant cause of childhood blindness worldwide. Current treatments primarily rely on anti-VEGF agents, which occasionally produce off-target effects. Consequently, researchers are exploring alternative biological pathways to target retinal pathological neovascularization. A recent study suggests that the dopaminergic system plays a critical role in regulating abnormal vessel growth in the eye.

Specifically, the study utilized an oxygen-induced retinopathy (OIR) mouse model to understand the role of dopamine. Researchers found that OIR leads to a distinct dopaminergic deficiency. This deficiency impairs the activity of dopamine D2 receptors (Drd2) located on Müller cells. Moreover, integrated single-cell RNA sequencing revealed that Drd2-mediated signaling governs the biosynthesis of hypoxia-inducible factor alpha. Therefore, impaired Drd2 activity directly contributes to the progression of ROP by allowing growth factors to proliferate unchecked.

Inhibiting Retinal Pathological Neovascularization via Drd2 Signaling

The investigation examined various dopamine receptor agonists and antagonists to determine their therapeutic potential. Specifically, apomorphine, a non-selective agonist, effectively inhibited vessel proliferation. Furthermore, Müller cell-specific Drd2 knockout mice exhibited worsened outcomes, confirming the protective role of these receptors. Additionally, the study showed that restoring Drd2 signaling reduces vascular endothelial growth factor A (VEGF-A) levels. This finding suggests that dopaminergic agents might complement current anti-VEGF therapies in the future.

In addition to therapeutic potential, this research highlights the importance of Müller cells in retinal health. These cells act as mediators between neuronal activity and vascular stability. Consequently, understanding their interaction with dopamine provides a foundation for future clinical trials. Scientists hope that these insights will lead to more consistent outcomes for premature infants at risk of blindness.

Frequently Asked Questions

How does dopamine affect retinal health in premature infants?

Dopamine acts as a neuromodulator that helps regulate retinal vascular development. A deficiency in dopamine or its receptors can trigger the uncontrolled growth of blood vessels, which leads to vision loss in conditions like ROP.

What are the current limitations of anti-VEGF treatments for ROP?

While effective, anti-VEGF agents can have variable efficacy and may cause off-target effects in the developing eye and systemic circulation. Researchers are looking for more specific targets, such as Drd2 receptors, to improve treatment safety.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Wang Q et al. Dopamine inhibits retinal pathological neovascularization in the oxygen-induced retinopathy mouse model. J Pathol. 2026 Jun 03. doi: 10.1002/path.70080. PMID: 42237060.


2. Hellström A et al. Retinopathy of prematurity. Lancet. 2013;382(9892):1445-57.


3. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108(1):17-40.